Reviva announces full details of positive phase 2 clinical trial results for acute schizophrenia

Cupertino, calif., april 26, 2021 (globe newswire) -- reviva pharmaceuticals holdings, inc. (nasdaq: rvph) (along with its subsidiaries, “reviva” or the “company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (cns), cardiovascular, metabolic, and inflammatory diseases, today announced the full details of its phase 2 clinical trial for its lead drug candidate, rp5063 (brilaroxazine) for acute schizophrenia.
RVPH Ratings Summary
RVPH Quant Ranking